Apimeds Pharmaceuticals Faces Investigation Over Alleged Misleading Shareholder Statements

New York, Monday, 27 April 2026.
On April 27, 2026, an investigation was launched into Apimeds Pharmaceuticals to determine if the biotechnology firm misled investors, signaling critical compliance risks for current shareholders.